RAPID
A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Collaborators
- Moffitt Cancer Center, The University of Kansas Medical Center, City of Hope Medical Center
- Tags
- T Cell (Allogeneic), High Risk
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2144
- NCT Identifier
- NCT06552416
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.